ADC Therapeutics SA - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ADCT New York 8731 https://adctherapeutics.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for ADC Therapeutics SA

Pliant Therapeutics (PLRX) Surges 44% in A Week: Here's Why - Jan 25th, 2023 3:21 pm
Amarin Corporation (AMRN) Down 13% in One Week: Here's Why - Jan 23rd, 2023 4:01 pm
Wall Street Analysts Think ADC Therapeutics SA (ADCT) Could Surge 174.2%: Read This Before Placing a Bet - Jan 16th, 2023 2:55 pm
ADC Therapeutics SA (ADCT) Stock Jumps 21.8%: Will It Continue to Soar? - Jan 13th, 2023 12:28 pm
ADC Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference - Jan 4th, 2023 12:15 pm
ADC Therapeutics Appoints Mohamed Zaki as Chief Medical Officer - Jan 3rd, 2023 9:30 pm
ADC Therapeutics and Sobi Announce European Commission Approval of ZYNLONTA® (loncastuximab tesirine) for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma - Dec 21st, 2022 7:00 am
ADC Therapeutics Appoints Jose Carmona as Chief Financial Officer - Dec 19th, 2022 12:15 pm
FREENOME PRESENTS RESEARCH HIGHLIGHTING THE PROMISE OF IDENTIFYING DRUG-RESPONSE BIOMARKERS FOR DLBCL PATIENTS - Dec 12th, 2022 1:00 pm
FDA Takes Tougher Line on Fast-Tracked Drugs - Dec 5th, 2022 10:30 am
Biocytogen Enters into Antibody Agreement with ADC Therapeutics - Nov 28th, 2022 2:47 pm
The past year for ADC Therapeutics (NYSE:ADCT) investors has not been profitable - Nov 16th, 2022 12:05 pm
ADC Therapeutics SA (ADCT) Reports Q3 Loss, Tops Revenue Estimates - Nov 8th, 2022 1:15 pm
ADC Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates - Nov 8th, 2022 12:00 pm
ADC Therapeutics to Participate in the Jefferies London Healthcare Conference - Nov 7th, 2022 12:15 pm
Arcturus Therapeutics (ARCT) Surges 18.7%: Is This an Indication of Further Gains? - Nov 4th, 2022 9:46 am
ADC Therapeutics Announces Abstracts Accepted for Presentation at the 64th ASH Annual Meeting - Nov 3rd, 2022 1:34 pm
IGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evaluate Imvotamab (IGM-2323) in Combination with ZYNLONTA® in Patients with Relapsed or Refractory B Cell Non-Hodgkin’s Lymphoma - Nov 2nd, 2022 8:05 pm
ADC Therapeutics Appoints Kristen Harrington-Smith as Chief Commercial Officer and Peter Graham as Chief Legal Officer - Nov 1st, 2022 11:15 am
ADC Therapeutics to Host Third Quarter 2022 Financial Results Conference Call on November 8, 2022 - Oct 31st, 2022 11:15 am